Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DYN NASDAQ:GPCR NYSE:RCUS NASDAQ:ZSQR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$19.80+3.1%$18.30$8.06▼$25.00$3.17B1.091.56 million shs5.11 million shsGPCRStructure Therapeutics$44.51-1.1%$42.89$15.80▼$94.90$3.20B-1.35699,132 shs1.15 million shsRCUSArcus Biosciences$24.39+1.1%$24.17$7.91▼$28.72$3.03B0.851.04 million shs2.31 million shsZSQRCoeptis Therapeutics$16.73+7.3%$12.16$6.80▼$21.41$801.82M-0.22322,248 shs1.11 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics+3.13%+10.31%+24.37%+12.76%+83.67%GPCRStructure Therapeutics-1.09%+2.79%+24.05%-8.24%+105.87%RCUSArcus Biosciences+0.99%+4.38%+7.10%+12.45%+185.80%ZSQRCoeptis Therapeutics+7.31%+53.49%+74.45%+48.05%+116.71%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDYNDyne Therapeutics$19.80+3.1%$18.30$8.06▼$25.00$3.17B1.091.56 million shs5.11 million shsGPCRStructure Therapeutics$44.51-1.1%$42.89$15.80▼$94.90$3.20B-1.35699,132 shs1.15 million shsRCUSArcus Biosciences$24.39+1.1%$24.17$7.91▼$28.72$3.03B0.851.04 million shs2.31 million shsZSQRCoeptis Therapeutics$16.73+7.3%$12.16$6.80▼$21.41$801.82M-0.22322,248 shs1.11 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDYNDyne Therapeutics+3.13%+10.31%+24.37%+12.76%+83.67%GPCRStructure Therapeutics-1.09%+2.79%+24.05%-8.24%+105.87%RCUSArcus Biosciences+0.99%+4.38%+7.10%+12.45%+185.80%ZSQRCoeptis Therapeutics+7.31%+53.49%+74.45%+48.05%+116.71%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDYNDyne Therapeutics 2.93Moderate Buy$33.8570.94% UpsideGPCRStructure Therapeutics 2.89Moderate Buy$106.75139.83% UpsideRCUSArcus Biosciences 2.58Moderate Buy$35.1043.91% UpsideZSQRCoeptis Therapeutics 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ZSQR, GPCR, DYN, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2026GPCRStructure Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$100.00 ➝ $70.006/4/2026RCUSArcus Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$46.005/18/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00 ➝ $35.005/15/2026DYNDyne Therapeutics EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$33.005/13/2026DYNDyne Therapeutics Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Perform$23.00 ➝ $24.005/11/2026RCUSArcus Biosciences Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$20.00 ➝ $22.005/7/2026RCUSArcus Biosciences The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $34.005/4/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/27/2026GPCRStructure Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$101.004/27/2026GPCRStructure Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$101.004/21/2026GPCRStructure Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDYNDyne TherapeuticsN/AN/AN/AN/A$6.81 per shareN/AGPCRStructure TherapeuticsN/AN/AN/AN/A$24.99 per shareN/ARCUSArcus Biosciences$247M12.42N/AN/A$5.84 per share4.18ZSQRCoeptis Therapeutics$1.36M632.66N/AN/A$2.63 per share6.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDYNDyne Therapeutics-$446.21M-$3.22N/AN/AN/AN/A-58.28%-46.77%7/27/2026 (Estimated)GPCRStructure Therapeutics-$141.20M-$0.87N/AN/AN/AN/A-24.91%-23.67%8/6/2026 (Estimated)RCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)ZSQRCoeptis Therapeutics-$11.92M-$2.52N/AN/AN/A-810.04%-92.29%-73.52%N/ALatest ZSQR, GPCR, DYN, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ZSQRCoeptis TherapeuticsN/A-$0.65N/A-$0.65N/A$0.11 million5/11/2026Q1 2026DYNDyne Therapeutics-$0.7723-$0.73+$0.0423-$0.73N/AN/A5/7/2026Q1 2026GPCRStructure Therapeutics-$0.39-$0.35+$0.04-$0.35$11.11 millionN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 million3/19/2026Q4 2025ZSQRCoeptis TherapeuticsN/A-$0.12N/A-$0.12N/A$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDYNDyne TherapeuticsN/AN/AN/AN/AN/AGPCRStructure TherapeuticsN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/AZSQRCoeptis TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDYNDyne Therapeutics0.1719.9219.92GPCRStructure TherapeuticsN/A26.1626.16RCUSArcus Biosciences0.194.044.04ZSQRCoeptis Therapeutics0.013.253.25Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDYNDyne Therapeutics96.68%GPCRStructure Therapeutics91.78%RCUSArcus Biosciences92.89%ZSQRCoeptis Therapeutics13.88%Insider OwnershipCompanyInsider OwnershipDYNDyne Therapeutics9.46%GPCRStructure Therapeutics5.50%RCUSArcus Biosciences9.60%ZSQRCoeptis Therapeutics24.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDYNDyne Therapeutics100165.31 million149.68 millionOptionableGPCRStructure Therapeutics13671.07 million67.17 millionOptionableRCUSArcus Biosciences500125.77 million113.70 millionOptionableZSQRCoeptis Therapeutics251.43 million38.96 millionNot OptionableZSQR, GPCR, DYN, and RCUS HeadlinesRecent News About These CompaniesCoeptis Therapeutics (NASDAQ:ZSQR) Downgraded to "Sell" Rating by Wall Street ZenJune 13, 2026 | americanbankingnews.comZ Squared to Participate in Maxim Group's AI Data Center SummitJune 9, 2026 | prnewswire.comZ Squared, Inc. Enters $50 Million Committed Equity Forward Purchase Agreement to Support AI Infrastructure BuildoutJune 4, 2026 | prnewswire.comZ Squared, Inc. Announces Preliminary Inclusion in Russell 3000® and Russell 2000® IndexesMay 27, 2026 | prnewswire.comVanderbilt Report: Z Squared Locks In Zero-Cash, Zero-Debt Path to 42 MW of AI-Ready PowerMay 26, 2026 | globenewswire.comZ Squared, Inc. Outlines Phase 1 Plan to Reach 100 MW of AI-Ready Infrastructure for Inference WorkloadsMay 19, 2026 | prnewswire.comZ Squared Appoints Jon Najarian, Pete Najarian, Marc LoPresti and Jay Zapata to Newly Formed Advisory BoardMay 4, 2026 | prnewswire.comZ Squared to Acquire Skycore Digital, Adding 24 MW of Energized AI Infrastructure with Expansion Path to 42 MWApril 29, 2026 | prnewswire.comZ Squared, Inc. to Ring the Nasdaq Closing Bell in Celebration of Its Listing on the Nasdaq Global MarketApril 28, 2026 | prnewswire.comCoeptis Therapeutics Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 27, 2026 | finanznachrichten.deZ Squared Provides Additional Information on Previously Disclosed Pro Rata DistributionApril 27, 2026 | tmcnet.comCoeptis Therapeutics Receives Shareholder Approval Towards Z Squared MergerApril 27, 2026 | finanznachrichten.deZ Squared Inc.: Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 25, 2026 | finanznachrichten.deZ Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global MarketApril 24, 2026 | prnewswire.comCoeptis Therapeutics: Coeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 9, 2026 | finanznachrichten.deWhy Coeptis Therapeutics Holdings, Inc.’s (COEP) Stock Is Up 10.60%April 9, 2026 | aaii.comACoeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing ApplicationApril 7, 2026 | markets.businessinsider.comNasdaq Approves Listing for Coeptis Therapeutics Holdings, Inc. Post-Merger with Z Squared Inc.April 7, 2026 | quiverquant.comQCoeptis Announces Approval of Z Squared Inc.'s Nasdaq Listing ApplicationApril 7, 2026 | globenewswire.comCoeptis Therapeutics: Vanderbilt Report: Coeptis / Z Squared Merger Enters Final Stretch - Closing Imminent as Institutional Tailwinds BuildMarch 9, 2026 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeZSQR, GPCR, DYN, and RCUS Company DescriptionsDyne Therapeutics NASDAQ:DYN$19.80 +0.60 (+3.13%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$19.98 +0.18 (+0.93%) As of 06/18/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Structure Therapeutics NASDAQ:GPCR$44.51 -0.49 (-1.09%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$44.31 -0.20 (-0.45%) As of 06/18/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.Arcus Biosciences NYSE:RCUS$24.39 +0.27 (+1.12%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$24.18 -0.21 (-0.86%) As of 06/18/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.Coeptis Therapeutics NASDAQ:ZSQR$16.73 +1.14 (+7.31%) As of 06/18/2026 04:00 PM EasternCoeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge Jabil Just Gave Investors a Stronger Reason to Buy the Dip USA Rare Earth Just Moved Closer to Commercial Reality After an Initial Panic, Wall Street's Leaning Into Apple's New Siri AI CoreWeave Insider Sales Look Big, But Should Investors Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
